Despite recent progress in treating lung cancer, it remains the leading cause of cancer death in the U.S. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 84% of diagnoses. People affected by this disease may have a reason to feel more optimistic about available treatments. A new treatment option that harnesses the body’s immune system is now available for certain patients.
OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) as a first treatment for adults with a type of advanced stage lung cancer (called non-small cell lung cancer) when your lung cancer has spread to other parts of your body (metastatic) and tumors are positive for PD-L1, but do not have an abnormal EGFR or ALK gene.
Support for patients and caregivers is also important. LUNGevity is the nation's leading lung cancer organization investing in lifesaving research and providing support services and education for patients and caregivers.
Learn more about treatment options, support services, and more here.